ArticleInternational journal for parasitology. Drugs and drug resistance2017
Therapeutic effect of ursolic acid in experimental visceral leishmaniasis.
Article in International journal for parasitology. Drugs and drug resistance, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 43 citations in OpenAlex.
- Combination Therapy and Phytochemical-Loaded Nanosytems for the Treatment of Neglected Tropical Diseases.Pharmaceutics · 2024Review
- Nanostructured Lipid Carriers as Robust Systems for Lupeol Delivery in the Treatment of Experimental Visceral Leishmaniasis.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Human Lung Cancer (A549) Cell Line Cytotoxicity and Anti-Pharmaceuticals (Basel, Switzerland) · 2022Article
- Recent Advances Regarding the Molecular Mechanisms of Triterpenic Acids: A Review (Part I).International journal of molecular sciences · 2022Review
- Preclinical Assessment of Ursolic Acid Loaded into Nanostructured Lipid Carriers in Experimental Visceral Leishmaniasis.Pharmaceutics · 2021Article
- The Potential of Traditional Knowledge to Develop Effective Medicines for the Treatment of Leishmaniasis.Frontiers in pharmacology · 2021Review
- Green Approach: ''A Forwarding Step for Curing Leishmaniasis-A Neglected Tropical Disease''.Frontiers in molecular biosciences · 2021Review
- Leishmanicidal Activity and Ultrastructural Changes of Maslinic Acid Isolated fromEvidence-based complementary and alternative medicine : eCAM · 2021Article
- Ursolic Acid Potentializes Conventional Therapy in Experimental Leishmaniasis.Pathogens (Basel, Switzerland) · 2020Article
- Dataset on recombinant expression of an ancient chitinase gene from different species ofData in brief · 2020Article
- Evaluating the Potential of Ursolic Acid as Bioproduct for Cutaneous and Visceral Leishmaniasis.Molecules (Basel, Switzerland) · 2020Article
- Use of Natural Products in Leishmaniasis Chemotherapy: An Overview.Frontiers in chemistry · 2020Review
- In vitro and in vivo immunomodulatory properties of octyl-β-D-galactofuranoside during Leishmania donovani infection.Parasites & vectors · 2019Article
- The Mechanism of Action of Ursolic Acid as a Potential Anti-Toxoplasmosis Agent, and Its Immunomodulatory Effects.Pathogens (Basel, Switzerland) · 2019Article
- Asteraceae Plants as Sources of Compounds Against Leishmaniasis and Chagas Disease.Frontiers in pharmacology · 2019Review
- Evaluation of Anti-Pharmaceuticals (Basel, Switzerland) · 2018Article
- Antiparasitic activity in Asteraceae with special attention to ethnobotanical use by the tribes of Odisha, India.Parasite (Paris, France) · 2018Review
- Synergy between Ursolic and Oleanolic Acids from Vitellaria paradoxa Leaf Extract and β-Lactams against Methicillin-Resistant Staphylococcus aureus: In Vitro and In Vivo Activity and Underlying Mechanisms.Molecules (Basel, Switzerland) · 2017Article
- Investigation the effect of the aqueous extract ofTropical parasitologyArticle
Corrections and comments
- Erratum issuedCorrigendum to "Therapeutic effect of ursolic acid in experimental visceral leishmaniasis" [Int. J. Parasitol. Drugs Drug Resist. 7 (2017) 1-11].2017 · Gomes, Gabriela S [corrected to Santos-Gomes, Gabriela]
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leishmaniasis is an important neglected tropical disease, affecting more than 12 million people worldwide. The available treatments are not well tolerated and present diverse side effects in patients, justifying the search for new therapeutic compounds. In the present study, the therapeutic potential and toxicity of ursolic acid (UA), isolated from the leaves of Baccharis uncinella C. DC. (Asteraceae), were evaluated in experimental visceral leishmaniasis. To evaluate the therapeutic potential of UA, hamsters infected with L. (L.) infantum were treated daily during 15 days with 1.0 or 2.0 mg UA/kg body weight, or with 5.0 mg amphotericin B/kg body weight by intraperitoneal route. Fifteen days after the last dose, the parasitism of the spleen and liver was stimated and the main histopathological alterations were recorded. The proliferation of splenic mononuclear cells was evaluated and IFN-γ, IL-4, and IL-10 gene expressions were analyzed in spleen fragments. The toxicity of UA and amphotericin B were evaluated in healthy golden hamsters by histological analysis and biochemical parameters. Animals treated with UA had less parasites in the spleen and liver when compared with the infected control group, and they also showed preservation of white and red pulps, which correlate with a high rate of proliferation of splenic mononuclear cells, IFN-γ mRNA and iNOS production. Moreover, animals treated with UA did not present alterations in the levels of AST, ALT, creatinine and urea. Taken together, these findings indicate that UA is an interesting natural compound that should be considered for the development of prototype drugs against visceral leishmaniasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.